Key result
Ezetimibe/simvastatin shows no benefit over placebo for major events in asymptomatic aortic stenosis.
Why the study?
Does ezetimibe/simvastatin 10/40 mg/day reduce aortic valve surgery and ischemic vascular events in patients with asymptomatic aortic stenosis?
RCT (n=1,873)
Double-blind
randomized
Yes
Does ezetimibe/simvastatin 10/40 mg/day reduce aortic valve surgery and ischemic vascular events in patients with asymptomatic aortic stenosis?
The SEAS study is a large randomized trial designed to determine the prognostic value of aggressive lipid lowering with ezetimibe/simvastatin in patients with asymptomatic aortic stenosis.
No takes yet. Share an insight, caveat, or question.
Large RCT will test if ezetimibe/simvastatin reduces valve surgery and ischemic events in asymptomatic AS; delivers first major randomized evidence.
Rossebø et al. (2007) conducted an RCT in asymptomatic aortic stenosis (n=1,873). ezetimibe/simvastatin vs. placebo was evaluated on aortic valve surgery and ischemic vascular events, including cardiovascular mortality. The SEAS study randomized 1,873 patients with asymptomatic aortic stenosis to ezetimibe/simvastatin 10/40 mg/day or placebo to evaluate cardiovascular outcomes over a minimum of 4 years.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: